請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4000
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張美惠(Mei-Hwei Chang) | |
dc.contributor.author | Kai-Chi Chang | en |
dc.contributor.author | 張凱琪 | zh_TW |
dc.date.accessioned | 2021-05-13T08:40:10Z | - |
dc.date.available | 2021-02-24 | |
dc.date.available | 2021-05-13T08:40:10Z | - |
dc.date.copyright | 2016-02-24 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-02-03 | |
dc.identifier.citation | Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol. 2004;4:553-64.
Benhenda S, Cougot D, Buendia MA, Neuveut C. Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv Cancer Res. 2009;103:75-109. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol. 1996;70:4978-85. Birrer RB, Birrer D, Klavins JV. Hepatocellular carcinoma and hepatitis virus. Ann Clin Lab Sci. 2003;33:39-54. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol. 2004;78:12725-34. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol. 2008;8:911-22 Busca A, Kumar A.Innate immune response in hepatitis B virus (HBV) infection. Virol J. 2014;11:22. Chang MH. Natural history and clinical management of the chronic hepatitis B virus infection in children. Hepatol Int. 2008;2:28-36. Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, Jones J, Hughes J, Milich DR. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A. 2004;101:14913-8. Chen WN, Oon CJ, Leong AL, Koh S, Teng SW. Expression of integrated hepatitis B virus X variants in human hepatocellular carcinomas and its significance. Biochem Biophys Res Commun. 2000;276:885-92. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29-60. Chu CM, Karayiannis P, Fowler MJ, Monjardino J, Liaw YF, Thomas HC. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology. 1985;5:431-4. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology. 2009;137:1289-300. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut. 2009;58:974-82. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006;1:23-61. Hoffmann HH, Schneider WM, Rice CM. Interferon and viruses: an evolutionay arms race of molecular interactions. Trends Immunol. 2015;36:124-38. Iavarone M, Trabut JB, Delpuech O, Carnot F, Colombo M, Kremsdorf D, Bréchot C, Thiers V. Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol. 2003;39:253-61. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta- producing cells link innate and adaptive immunity. J Exp Med. 2000;192:219-26. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:144-52. Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, Kurokawa K. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology. 1994;19:810-9. Koumbi L, Bertoletti A, Anastasiadou V, Machaira M, Goh W, Papadopoulos NG, Kafetzis DA, Papaevangelou V. Hepatitis B-specific T helper cell responses in uninfected infants born to HBsAg+/HBeAg- mothers. Cell Mol Immunol. 2010;7:454-8. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 2006;25:3823-33. Kuang SY, Jackson PE, Wang JB, Lu PX, Munoz A, Qian GS, Kensler TW, Groopman JD. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A. 2004;101:3575-80. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol. 2007;7:379-90. Li SK, Ho SF, Tsui KW, Fung KP, Waye MY. Identification of functionally important amino acid residues in the mitochondria targeting sequence of Hepatitis B virus X protein. Virology. 2008;381:81-88. Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013;33:97-102. Luangsay S, Gruffaz M, Isorce N, Testoni B, Michelet M, Faure-Dupuy S, Maadadi S, Ait-Goughoulte M, Parent R, Rivoire M, Javanbakht H, Lucifora J, Durantel D, Zoulim F. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol. 2015;63:1314-22. Marchant A, Appay V, van der Sande M, Dulphy N, Liesnard C, Kidd M, Kaye S, Ojuola O, Gillespie GM, Vargas Cuero AL, Cerundolo V, Callan M, McAdam KP, Rowland-Jones SL, Donner C, McMichael AJ, Whittle H. Mature CD81 T lymphocyte response to viral infection during fetal life. J Clin Invest. 2003;111:1747-55. Ni YH, Chang MH, Hsu HY, Chen HL. Long-term follow-up study of core gene deletion mutants in children with chronic hepatitis B virus infection. Hepatology. 2000;32:124-8. Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, Yeh SH, Jeng YM, Tsai KS, Chen DS. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology. 2004;127:1733-8. Poussin K, Dienes H, Sirma H, Urban S, Beaugrand M, Franco D, Schirmacher P, Bréchot C, Paterlini Bréchot P. Expression of mutated hepatitis virus X genes in human hepatocellular carcinomas. Int J Cancer. 1999;80:497-505. Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, Dusheiko G, Williams R, Maini MK, Bertoletti A. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 2002;195:1089-101. Takada S, Kaneniwa N, Tsuchida N, Koike K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene - transfected cells. Oncogene. 1997;15:1895-901. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009; 27:75-86. Thomas M, Whitten, Anne T, QUETS, Robert H, Schloemer. Identification of the hepatitis B virus factor that inhibits expression of beta interferon gene. J virol. 1991; 65:4699-4704. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133-46. Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, Paterlini-Bréchot P, Bréchot C, Kremsdorf D. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res. 2001;61:7803-10. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, Van Rysselberge M, Twité N, Goldman M, Marchant A, Willems F. Human cytomegalovirus elicits fetal T cell responses in utero. J Exp Med. 2010;207:807-821. Wang WH, Grégori G, Hullinger RL, Andrisani OM. Sustained activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase pathways by hepatitis B virus X protein mediates apoptosis via induction of Fas/FasL and tumor necrosis factor (TNF) receptor 1/TNF-alpha expression. Mol Cell Biol. 2004;24:10352-65. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Yang X, Wang Y, Wen C, Wu Q, Shi W, Zhong H. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol. 2010;185:1158-1168. Wei Y, Neuveut C, Tiollais P, Buendia MA. Molecular biology of the hepatitis B virus and role of the X gene. Pathol Biol. 2010;58:267-72. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA. 2004;101:6669-74. Wieland SF, Vega RG, Müller R, Evans CF, Hilbush B, Guidotti LG, Sutcliffe JG, Schultz PG, Chisari FV. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol. 2003;77:1227-36. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007; 46:1769-78. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF. HBV suppresses Toll-like receptor mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology. 2009;49:1132-40. Wu JF, Su YR, Chen CH, Chen HL, Ni YH, Hsu HY, Chang MH. Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotypes B and C HBV-infected children. J Pediatr Gastroenterol Nutr. 2012;54:97-100. Yang HI,Lu SN, Liaw TF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS; Taiwan Community-Based Cancer Screening Project Group. Hepatitis Be antigen and the risk of hepatocellular carcinoma. NEJM 2002. 347(3), 168-74. Yeh CT, Shen CH,Tai DI, Chu CM, Liaw YF. Identification and characterization of prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene. 2000; 19: 5213-20. Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology. 2010;52:1922-33. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol. 2004;41:659-66. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4000 | - |
dc.description.abstract | 中文摘要
研究背景及目的 慢性B型肝炎感染是一個全球的健康議題。持續性的B型肝炎感染常常會演變成為慢性肝臟發炎或是肝癌。B型肝炎感染,流行地區例如--台灣,通常開始於嬰幼兒期,並主要藉由母嬰垂直感染而使兒童成為帶原者。兒童的慢性B型肝炎感染在年幼時期通常沒有症狀,這段免疫耐受期通常會持續15年甚至更久。 B型肝炎病毒如何躲匿並對抗宿主固有的先天性免疫,並使患童不產生免疫反應的機制目前還是未明。近來發現B肝病毒功能性基因之一的HBx基因可能在B型肝炎自然病史中扮演了某種重要的角色。HBx基因的變異也曾被報導與肝臟腫瘤發生的原因相關。然而,對慢性B型肝炎兒童來說, HBx基因的變異是否跟免疫耐受期(immune tolerance phase)的維持或結束有關係,目前仍然不清楚。HBx基因的突變對於兒童慢性B型肝炎的長程自然病史之影響仍然有待研究。我們希望探討HBx基因變異與兒童慢性B型肝炎感染長程病史之間的交互作用。 研究方法 臺大醫院兒童肝膽腸胃科自兒童期開始對一群慢性B型肝炎感染的患者做成長程追蹤。自幼年開始,他們在門診規律性定期接受病史詢問及理學檢查,並且也接受抽血檢驗,其中包括肝轉胺酶、B型肝炎病毒標記(HBsAg, HBeAg, Anti-HBe, Anti-HBs, Anti-HBc)、胎兒蛋白、B型肝炎病毒去氧核醣核酸的定量、與B肝病毒基因型測定等。在這些慢性B型肝炎感染的個案中,我們追蹤未曾接受B型肝炎抗病毒藥物治療、未合併有其他C型肝炎或D型肝炎…等可能導致肝臟發炎因素的病患,取其兒童期第一次接受抽血檢查之血清,萃取其中的B型肝炎病毒去氧核醣核酸,並進行HBx基因的定序。接著與已知資訊中的HBx基因序列進行比對並分析,以找出突變點,並且與臨床資料整合做分析, 我們希望能探討B肝病童之HBx基因突變與免疫耐受期長度以及與自然病程之間的關連性。 研究結果 在這個研究中,我們追蹤了155位同意加入本研究之病患至少5年以上,其中有105位是男性。他們平均起始追蹤年紀為8.9± 4.5歲,平均追蹤時間為23.4± 6.7年。有110位病患在追蹤期間經歷了免疫耐受期的結束,並且有81位患者經過B型肝炎e抗原抗體轉換的過程。根據155位患者聚合酶連鎖反應附帶分析比對,基因型B型占所有病患的77.4%。另外, HBx基因出現機率最高的突變位點有五個,包括V44G/L, A66T, R87G, N118T, I127V。利用Kaplan-Meier存活分析,我們發現基因型B型、HBx基因的R87V、 N118T、以及I127V突變,相較於基因型C型及沒有發生突變者,有較高的比例容易結束免疫耐受期而進入到免疫廓清期(發炎期),並且達到統計學上的顯著意義(p<0.001, p=0.017, 0.044, 0.001)﹔在多變項分析,僅有HBx基因的I127V突變發現到有較高的機會較早突破免疫耐受期而進入到免疫廓清期,其HR為2.07; p值為0.022,達統計學上顯著意義。 結論 在慢性B型肝炎感染自然病史中, 我們發現HBx基因的I127V突變和較早突破免疫耐受期有顯著相關。 | zh_TW |
dc.description.abstract | Abstract
Backgrounds and Aims Chronic hepatitis B virus (HBV) infection is a world-wide health problem. Persistent HBV infection is often associated with chronic liver disease and may lead to liver cirrhosis and hepatocellular carcinoma (HCC). HBV infections were mostly acquired in the infancy and early childhood through the route of mother-to-infant transmission, especially in endemic areas such as Taiwan. Children with HBV infection often remained asymptomatic at their young age, and their immune tolerance phases may last 2 decades or longer. The mechanism of HBV to evade or overwhelm the human innate immune system, and to keep a state of relative hypo-responsiveness to HBV in children still remained largely unclear. Recently, HBx gene, which was one of the four HBV functional genes, had been reported to be involved in the host immune abrogation. However, the relationship between HBx mutation and either the persistence or the ending of immune tolerance was unknown. The impacts of HBx mutation on long term natural course of chronic HBV infection remained to be elucidated, particularly in children. We aim to investigate prognostic value of mutant HBx gene on the natural history of HBV infection from childhood to adult life. Materials and Methods Patients were recruited from long term prospective chronic HBV carrier cohort, which was conducted in Pediatric department of National Taiwan University Hospital. They received evaluations periodically including history taking and physical examinations. Liver enzymes, HBV markers (HBsAg, HBeAg, Anti-HBe, Anti-HBs, Anti-HBc), AFP, DNA quantitation, and HBV genotyping were also assessed. The blood samplings collected at initial time of enrollment were examined for HBx gene. We analyze the sequences of HBx genes and tried to find the mutations. We attempt to elucidate the correlations between HBx gene mutations and the lasting or ending of immune tolerance phase. Results A total of 155 children (105 males) were followed for 23.4± 6.7 years with initial age of 8.9± 4.5 years. Genotype B accounted for 77.4% of all patients according to sequence findings. One hundred and ten patients had breakthrough immune tolerance phase and 81 patients achieved HBe seroconversion. HBx gene mutations of V44G/L, A66T, R87G, N118T, I127V had highest frequencies. In Kaplan-Meier survival analysis, genotype B and mutants of R87V, N118T, and I127V in HBx gene had significantly higher cumulative proportion of breakthrough of immune tolerance phase (log rank test, p<0.001, p=0.017, 0.044, and 0.001, respectively). In multivariate analysis, we found that mutation of I127V in HBx gene was an independent favorable factor to predict earlier breakthrough of immune tolerance phase, with a statistically significant value (hazard ratio 2.07, 95% CI 1.11-3.85, p=0.022) Conclusions In chronic HBV infection, patients with I127V mutation in HBx gene had higher potential to breakthrough the immune tolerance phase. | en |
dc.description.provenance | Made available in DSpace on 2021-05-13T08:40:10Z (GMT). No. of bitstreams: 1 ntu-105-P02421005-1.pdf: 1426308 bytes, checksum: c5b4a3b51e58d8d619cbbde53079fa05 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 目 錄
口試委員審定書………………………………………………… i 致謝 ……………………………………………………………………… ii 中文摘要……………………………………………………………… iii 英文摘要………………………………………………………………… v 碩士論文內容 一、 緒論 1.1 研究背景 ……………………………………… 1 1.1.1 慢性B型肝炎感染與免疫耐受 ………………………………. 1 1.1.2 HB x基因 ……………………………………… 1 1.1.3 抗病毒先天性免疫系統 ……………………………………… 2 1.1.3.1 MAVS蛋白質在宿主的先天性免疫系統扮演一個重要的角色 … 2 1.1.3.2 B型肝炎病毒利用多種策略逃脫先天性免疫系統的攻擊 … 3 1.1.3.3 HBx基因與宿主先天性免疫系統之間的關聯性 ………… 3 1.2 未解決的問題及假說 ……………………………………… 4 1.3 研究目的 ……………………………………… 4 二、研究方法及材料 2.1 研究對象 ……………………………………… 5 2.2 研究方法 ……………………………………… 6 2.2.1 B型肝炎病毒標記, 血清學檢測, 病毒定量, 基因型 ………6 2.2.2 B型肝炎X基因序列比對分析 ………………………………… 6 2.2.3 免疫組織化學染色法分析HBx蛋白質與MAVS蛋白質的表現… 7 2.3 統計方法 ……………………………………… 8 三、結果 3.1 免疫耐受期的結束 ……………………………………… 8 3.2 HBx 基因定序 ……………………………………… 9 3.3 影響免疫耐受期的因素 ……………………………………… 9 3.4 比較不同時間點所測得之HBx蛋白突變 ………………… 10 3.5 使用免疫組織化學染色法研究肝臟組織切片內HBx蛋白質以及 MAVS蛋白質的表現 ……………………………………… 10 四、討論 ……………………………………… 11 五、結論及展望 ……………………………………… 13 六、論文英文簡述 ……………………………………… 15 七、參考文獻 ……………………………………… 33 八、圖表 ……………………………………… 41 | |
dc.language.iso | zh-TW | |
dc.title | B型肝炎X基因對於兒童B型肝炎感染自然病史所扮演的角色 | zh_TW |
dc.title | The role of Hepatitis B virus X gene on the natural history of hepatitis B virus infection | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 倪衍玄(Yen-Hsuan Ni),劉俊人(Chun-Jen Liu) | |
dc.subject.keyword | 慢性B型肝炎,B型肝炎x 基因,免疫耐受期,第一型干擾素,MAVS蛋白, | zh_TW |
dc.subject.keyword | Chronic hepatitis B infection,hepatitis B X gene,immune tolerance phase,type I interferon,MAVS protein, | en |
dc.relation.page | 48 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2016-02-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf | 1.39 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。